Status:
COMPLETED
Daily Avanafil for Erectile Dysfunction
Lead Sponsor:
University of Alexandria
Conditions:
Erectile Dysfunction
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
In this study, the investigators tried to study the effect of daily avanafil on the serum level of endothelial function markers, as well as its impact on the erectile function in males with erectile a...
Detailed Description
Avanafil is a highly selective and potent oral phosphodiesterase type 5 inhibitor (PDE5-I) . However, its impact on the soluble markers of endothelial function has not been investigated yet. This stud...
Eligibility Criteria
Inclusion
- Men with clinical diagnosis of erectile dysfunction of any severity.
- Should be associated with systemic disorders indicative of endothelial dysfunction
Exclusion
- \- Erectile dysfunction due to psychogenic causes, hypogonadism, or spinal cord injury.
Key Trial Info
Start Date :
September 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 10 2019
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04374994
Start Date
September 1 2018
End Date
October 10 2019
Last Update
September 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Alexandria University.
Alexandria, Elazareta, Egypt, 21500